Andere talen Fate Therapeutics, Inc.

Aandelen

FATE

US31189P1021

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,79 ^USD	-4,96%		-16,98%	+28,07%

19/03	Fate Therapeutics prijst $100 miljoen aanbieding, onderhandse plaatsing	MT
12/03	Transcript : Fate Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 11:15 AM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	03/04
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference	03/04
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	02/04
Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	21/03
Fate Therapeutics Prices $100 Million Offering, Private Placement	19/03
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement	19/03
Fate Therapeutics, Inc. announced that it expects to receive $19.996366 million in funding from Redmile Group, LLC	19/03
Fate Therapeutics, Inc.(NasdaqGM:FATE) added to S&P Biotechnology Select Industry Index	18/03
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	06/03
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	05/03
Fate Therapeutics to Present at Upcoming March Investor Conferences	04/03
Fate Therapeutics to Present at Upcoming March Investor Conferences	01/03
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Fate Therapeutics: Q4 Earnings Snapshot	26/02
Earnings Flash (FATE) FATE THERAPEUTICS Posts Q4 Revenue $1.7M, vs. Street Est of $1.5M	26/02
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	26/02
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/02
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results	15/02
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	02/02
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	02/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Fate Therapeutics, Inc.

Aandelen

FATE

US31189P1021

Andere talen

Filters